GlassScriptPhysician profile
Taylor Schrant
NPI 1780323030
$637.67
in general payments reported to CMS, 2019-2025
16 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $292 · 2024: $142 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $637.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $170.51 | 2023 | |
| Cranial Technologies, INC | $114.42 | 2024-2025 | Doc Band |
| Corium, LLC | $43.43 | 2025 | Azstarys |
| Merck Sharp & Dohme LLC | $37.91 | 2023-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Sanofi Pasteur INC. | $34.79 | 2024 | |
| Glaxosmithkline, LLC. | $34.50 | 2023-2025 | Rotarix, Pediarix, Bexsero |
| Sanofi-Aventis U.S. LLC | $32.84 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $29.79 | 2023 | Breztri |
| Collegium Pharmaceutical, INC. | $22.83 | 2025 | Jornay Pm |
| Mirum Pharmaceuticals, INC. | $21.22 | 2025 | Livmarli |
| Ironshore Pharmaceuticals INC. | $19.17 | 2024 | |
| Seqirus USA INC | $18.85 | 2025 | Flucelvax |
| Phadia US INC. | $16.57 | 2023 | Immunocap |
| Currax Pharmaceuticals LLC | $14.76 | 2023 | Onzetra Xsail, Contrave |
| Pfizer INC. | $13.10 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $12.98 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Schrant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.